The global filgrastim market was valued at $ 562.50 million in 2020 and is projected to reach $ 745.90 million by 2030 registering a CAGR of 2.80% from 2021 to 2030.
Filgrastim is a drug that is used to increase the production of granulocytes (a type of white blood cell) in patients who are receiving treatment that causes low white blood cell counts. Filgrastim is used to prevent infection and neutropenic (low white blood cells) fevers caused by chemotherapy. Filgrastim is a support medication used in this therapy. Filgrastim injection is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to bone marrow. Furthermore, filgrastim is in a class of medications called colony-stimulating factors. It aids the body's production of neutrophils. On the other hand, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting.
Factors such as increase in prevalence of various diseases and surge in geriatric population, drive the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. Conversely, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.
The global filgrastim market segmented on the basis of drug type, distribution channel, indication and region. On the basis of drug type, it is further classified into biologic and biosimilar. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Based on indication, it is categorized into chemotherapy induced netropenia, chronic neutropenia and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Filgrastim is a drug that is used to increase the production of granulocytes (a type of white blood cell) in patients who are receiving treatment that causes low white blood cell counts. Filgrastim is used to prevent infection and neutropenic (low white blood cells) fevers caused by chemotherapy. Filgrastim is a support medication used in this therapy. Filgrastim injection is also used to increase the chance of survival in people who have been exposed to harmful amounts of radiation, which can cause severe and life-threatening damage to bone marrow. Furthermore, filgrastim is in a class of medications called colony-stimulating factors. It aids the body's production of neutrophils. On the other hand, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting.
Factors such as increase in prevalence of various diseases and surge in geriatric population, drive the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. Conversely, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.
The global filgrastim market segmented on the basis of drug type, distribution channel, indication and region. On the basis of drug type, it is further classified into biologic and biosimilar. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Based on indication, it is categorized into chemotherapy induced netropenia, chronic neutropenia and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global filgrastim market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps understand the drug types of filgrastim market used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Drug Type
- Biologic
- Biosimilar
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Indication
- Chemotherapy induced Netropenia
- Chronic Neutropenia
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Abbott Laboratories
- Amgen
- Apotex
- Cadila Pharmaceuticals
- Dr. Reddy's Laboratories "
- Kirin Holding (Kyowa Kirin)
- Novartis
- Pfizer
- Teva Pharmaceutical Industries Ltd
- Toksöz Group (Arven)
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: FILGRASTIM MARKET, BY DRUG TYPE
CHAPTER 5: FILGRASTIM MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 6: FILGRASTIM MARKET, BY INDICATION
CHAPTER 7: FILGRASTIM MARKET, BY REGION
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Amgen
- Apotex
- Cadila Pharmaceuticals
- Dr. Reddy's Laboratories
- Kirin Holding (Kyowa Kirin)
- Novartis
- Pfizer
- Teva Pharmaceutical Industries Ltd.
- Toksöz Group (Arven)
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | October 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 562.5 million |
| Forecasted Market Value ( USD | $ 745.9 million |
| Compound Annual Growth Rate | 2.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
